Cavernous sinus syndrome as the first presenting sign of metastatic cholangiocarcinoma

Authors

  • MARIA SOFIA COTELLI NEUROLOGY UNIT ASST VALCAMONICA, ESINE
  • MICHELE FRIGERIO NEURORADIOLOGY UNIT ASST SPEDALICIVILI BRESCIA (ITALY)
  • PATRIZIA CIVELLI NEUROLOGY UNIT ASST VALCAMONICA -ESINE (BRESCIA, ITALY)
  • MARTA BIANCHI NEUROLOGY UNIT ASST VALCAMONICA (ESINE, BRESCIA-ITALY)
  • FILIPPO MANELLI EMERGENCY UNIT ASST BERGAMO EST (SERIATE, BERGAMO-ITALY)
  • MARINELLA TURLA NEUROLOGY UNIT ASST VALCAMONICA (ESINE, BRESCIA-ITALY)

DOI:

https://doi.org/10.54029/2023drm

Keywords:

cholangiocarcinoma, metastases, tolosa Hunt, cavernous sinus syndrome

Abstract

Cholangiocarcinoma is poorly treatable and highly lethal adenocarcinoma of the hepatobiliary system. The incidence of brain metastases was 0.15%, 0.47% and 1.4% in three large case series. Cavernous sinus syndrome (CSS) refers to any disease involving the cavernous sinus. It is characterized by ophthalmoplegia, proptosis, chemosis, but also trigeminal sensory loss and Horner’s syndrome. We report the case of a 56-year-old Caucasian woman evaluated due to partial Horner syndrome, periorbital and retroorbital unilateral moderate-to-severe headache involving the left frontal and temporal areas of about 2 weeks duration.

Published

2023-07-01

Issue

Section

Correspondence